Free Trial

Trexquant Investment LP Has $2.29 Million Holdings in CryoPort, Inc. $CYRX

CryoPort logo with Transportation background

Key Points

  • Trexquant Investment LP increased its holdings in CryoPort, Inc. (NASDAQ:CYRX) by 57.7%, now owning 377,127 shares valued at approximately $2.29 million.
  • Wall Street analysts are optimistic about CryoPort, with a consensus rating of "Buy" and a target price of $12.00, following multiple upgrades and positive research reports.
  • CryoPort reported earnings with a loss per share of ($0.29), missing expectations, but surpassed revenue estimates with $45.45 million for the quarter.
  • Interested in CryoPort? Here are five stocks we like better.

Trexquant Investment LP raised its position in shares of CryoPort, Inc. (NASDAQ:CYRX - Free Report) by 57.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 377,127 shares of the company's stock after acquiring an additional 137,989 shares during the period. Trexquant Investment LP owned approximately 0.75% of CryoPort worth $2,293,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. lifted its stake in shares of CryoPort by 148.7% during the fourth quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock worth $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC acquired a new position in shares of CryoPort during the fourth quarter worth about $51,000. SBI Securities Co. Ltd. lifted its stake in shares of CryoPort by 548,750.0% during the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock worth $67,000 after purchasing an additional 10,975 shares in the last quarter. CWM LLC lifted its stake in shares of CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after purchasing an additional 10,591 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in shares of CryoPort by 4,434.6% during the first quarter. GAMMA Investing LLC now owns 14,556 shares of the company's stock worth $89,000 after purchasing an additional 14,235 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company's stock.

Analyst Ratings Changes

CYRX has been the topic of a number of recent research reports. Leerink Partners upgraded CryoPort from a "market perform" rating to an "outperform" rating and set a $16.00 price objective on the stock in a research note on Wednesday, August 6th. KeyCorp raised CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 price target for the company in a report on Wednesday, August 6th. BTIG Research reduced their price target on CryoPort from $13.00 to $10.00 and set a "buy" rating for the company in a report on Monday, July 7th. Leerink Partnrs raised CryoPort from a "hold" rating to a "strong-buy" rating in a report on Wednesday, August 6th. Finally, Stephens assumed coverage on CryoPort in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $13.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $12.00.

Read Our Latest Report on CryoPort

CryoPort Stock Down 0.0%

NASDAQ CYRX traded down $0.01 on Tuesday, hitting $10.04. 119,546 shares of the stock traded hands, compared to its average volume of 537,017. The stock has a 50-day moving average of $8.08 and a 200 day moving average of $6.82. CryoPort, Inc. has a twelve month low of $4.58 and a twelve month high of $10.46. The company has a market capitalization of $502.42 million, a P/E ratio of 7.58 and a beta of 1.62. The company has a current ratio of 16.24, a quick ratio of 15.47 and a debt-to-equity ratio of 0.39.

CryoPort (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). The company had revenue of $45.45 million for the quarter, compared to analyst estimates of $41.74 million. CryoPort had a negative return on equity of 9.79% and a net margin of 37.21%. CryoPort has set its FY 2025 guidance at EPS. As a group, analysts expect that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Robert J. Hariri sold 5,000 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $8.60, for a total value of $43,000.00. Following the sale, the director directly owned 26,275 shares in the company, valued at $225,965. This trade represents a 15.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Robert Stefanovich sold 9,300 shares of the stock in a transaction on Tuesday, August 19th. The shares were sold at an average price of $8.67, for a total value of $80,631.00. Following the transaction, the chief financial officer directly owned 207,213 shares of the company's stock, valued at approximately $1,796,536.71. The trade was a 4.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 435,125 shares of company stock valued at $2,992,628 in the last quarter. 10.10% of the stock is owned by insiders.

About CryoPort

(Free Report)

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.

See Also

Institutional Ownership by Quarter for CryoPort (NASDAQ:CYRX)

Should You Invest $1,000 in CryoPort Right Now?

Before you consider CryoPort, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.

While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.